Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas

Trial Profile

A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Brain tumour initiating cell vaccine (Primary) ; Imiquimod (Primary)
  • Indications Astrocytoma; Glioma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019.
    • 21 Nov 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top